Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 2, 2021

LoA Update: Affimed’s Phase I B-cell non-Hodgkin lymphoma asset has LoA drop by 14 points after release of preclinical data

Affimed’s Phase I AFM13 had its Likelihood of Approval (LoA) in B-cell non-Hodgkin lymphoma slashed in half on the back of preclinical data released on 13 May.

By Reynald Castañeda

Affimed’s Phase I AFM13 had its Likelihood of Approval (LoA) in B-cell non-Hodgkin lymphoma slashed in half on the back of preclinical data released on 13 May. The data showed that Hodgkin lymphoma patient-derived natural killer (NK) cells, when combined with AFM13, did not reach the same level of cytotoxicity compared with healthy donor-derived NK cells.

AFM13 previously had an LoA of 28%, dropping to 14% as of 17 May. The 14-point drop was determined analysed from a combination of machine learning and proprietary algorithm.

The investigator-led Phase I AFM13 trial is recruiting 30 recurrent or refractory CD30-positive Hodgkin or non-Hodgkin lymphoma patients. AFM13 works by inducing the innate immune system to eliminate CD30-positive hematologic tumour cells. It is the company’s most advanced asset featuring its innate cell engager mechanism.

Affimed has a $1.11bn market cap.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU